HMGB1 and B-cell chronic lymphocytic leukemia: Following 24 h of SpiD3 treatment, primary CLL samples demonstrated a statistically significant increase in HMGB1-associated luminescence compared to those of the vehicle and etoposide, while the prominent CLL therapeutic, ibrutinib, was incapable of evoking HMGB1 release (Figure 3E).